Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer [0.03%]
培美曲塞维持治疗非小细胞肺癌的疗效和安全性分析
Michel Velez,Belisario A Arango,Cesar A Perez et al.
Michel Velez et al.
Lung cancer incidence continues to rise and is the number one cause of cancer death in both men and women worldwide with projected 221,130 new cases and 156,940 deaths in the United States in 2011.1 Non-small cell lung cancer (NSCLC) repres...
Miriam López-Gómez,María Merino,Enrique Casado
Miriam López-Gómez
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been develope...
Malignant ovarian tumors with induced expression of carbonyl reductase show spontaneous regression [0.03%]
表达诱导型羰基还原酶的恶性卵巢肿瘤可自发消退
Hui Wang,Yoshihito Yokoyama,Shigeki Tsuchida et al.
Hui Wang et al.
Background: The present study investigated tumor proliferation in a tumor model using murine ovarian cancer cells with increased carbonyl reductase (CR) expression. ...
Jin Lee,Colin McGuire
Jin Lee
Leiomyosarcoma is a heterogeneous tumor group, representing
Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia [0.03%]
成人急性淋巴细胞白血病的新兴药物疗法
Lydia Lee,Adele K Fielding
Lydia Lee
Acute lymphoblastic leukemia (ALL) treatment regimes are amongst the longest, most intensive and complex used in hematooncology. Despite this, while treatment of pediatric ALL is a success story, we are far from being able to ensure a durab...
Ahmed Rizk,Juergen Honegger,Monika Milian et al.
Ahmed Rizk et al.
Endogenous Cushing's syndrome is a grave disease that requires a multidisciplinary and individualized treatment approach for each patient. Approximately 80% of all patients harbour a corticotroph pituitary adenoma (Cushing's disease) with e...
Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer [0.03%]
TroVax治疗进展性去势抵抗性前列腺癌的临床疗效
Robert J Amato,Mika Stepankiw
Robert J Amato
With approximately 240,890 new cases expected in 2011, prostate cancer remains the leading cause of non-melanoma cancer deaths in men. Immunotherapies using viral vector-based delivery systems targeting tumor-specific antigens are being stu...
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities [0.03%]
转移性皮肤黑色素瘤的新疗法及其急性毒性的管理
Charlotte Lemech,Hendrik-Tobias Arkenau
Charlotte Lemech
The last 12 months have seen the beginning of a new era in the treatment options available for patients with metastatic cutaneous melanoma, a disease previously characterised by its poor prognosis and limited treatment options. Two mechanis...
Safety and efficacy of everolimus in adult patients with neuroendocrine tumors [0.03%]
成人神经内分泌肿瘤曲安奈德疗效和安全性的研究
Paul E Oberstein,M Wasif Saif
Paul E Oberstein
Neuroendocrine tumors (NETs) consist of a diverse family of tumors which are derived from the neuroendocrine system. Most NETs are well or moderately differentiated tumors with a relatively indolent growth pattern. However, these tumors can...
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin [0.03%]
复发或难治性霍奇金淋巴瘤的新药疗法：关于布雷基西莫单抗道妥戈玛利素的研究重点
Michelle Furtado,Simon Rule
Michelle Furtado
Hodgkins' lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the suc...